FY2024 Earnings Estimate for CRL Issued By Zacks Research

Charles River Laboratories International, Inc. (NYSE:CRL) – Investment analysts at Zacks Research decreased their FY2024 EPS estimates for Charles River Laboratories International in a report issued on Tuesday, October 29th. Zacks Research analyst R. Department now expects that the medical research company will earn $10.00 per share for the year, down from their prior forecast of $10.05. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.01 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q4 2024 earnings at $2.50 EPS, Q1 2025 earnings at $2.44 EPS, Q2 2025 earnings at $2.56 EPS, Q3 2025 earnings at $2.62 EPS, Q4 2025 earnings at $2.68 EPS, FY2025 earnings at $10.30 EPS, Q1 2026 earnings at $2.79 EPS, Q2 2026 earnings at $2.88 EPS, Q3 2026 earnings at $2.91 EPS and FY2026 earnings at $11.78 EPS.

A number of other research firms also recently weighed in on CRL. UBS Group reduced their price target on shares of Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $270.00 to $205.00 in a report on Thursday, August 8th. Bank of America lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $250.00 to $215.00 in a report on Wednesday, October 2nd. StockNews.com upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Finally, Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective for the company. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Trading Down 1.5 %

CRL opened at $178.58 on Thursday. The company’s 50 day moving average is $194.66 and its 200-day moving average is $210.05. Charles River Laboratories International has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.22 billion, a P/E ratio of 21.39, a PEG ratio of 5.11 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion.

Charles River Laboratories International announced that its board has initiated a stock repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Institutional Trading of Charles River Laboratories International

Several large investors have recently modified their holdings of CRL. Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares during the period. Wolff Wiese Magana LLC acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth approximately $32,000. Headlands Technologies LLC acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $41,000. Whittier Trust Co. of Nevada Inc. grew its position in shares of Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after buying an additional 193 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth approximately $79,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).